icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité TECENTRIQ (atezolizumab).
See also
Décision d'accès précoce
25/11/2022
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
MVmCyF9xzqghhB3q